Submissions for variant NM_000124.4(ERCC6):c.-15+3G>T

dbSNP: rs1010201937

Total submissions: 1

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego	RCV000853311	SCV000996157	likely pathogenic	Cockayne syndrome type 2	2018-06-11	criteria provided, single submitter	clinical testing	This variant has not been reported in the literature to best of our knowledge. It is absent from the gnomAD population database and thus is presumed to be rare. The c.-15+3G>T variant is predicted by multiple splicing prediction tools to affect splicing which may lead to altered protein function. Based on this evidence and the additional research functional testing performed (see below), this variant is classified as likely pathogenic. Research Functional Testing: Initial research functional testing from the patient's blood revealed a decrease in unscheduled DNA synthesis (UDS) (PMID: 29105242). Although this result is an indicator for decreased DNA repair, UDS may or may not be affected in patients with CS. Follow-up studies from the patient's dermal fibroblasts replicated the findings from the UDS results from peripheral blood. The recovery of RNA synthesis (RRS) was then performed from the patient's fibroblasts that revealed decreased RRS. This result is indicative of a defect in transcription-coupled nucleotide excision repair (TC-NER) and a functional impairment in the gene product of ERCC6. This result is established to be diagnostic for CS.